This collaboration leverages Ocugen's vaccine expertise, its R&D and regulatory capabilities in the US.In preparation for the development of COVAXIN in the US, Ocugen has assembled a Vaccine Scientific Advisory Board featuring leading academic and industry experts to evaluate the clinical and regulatory path to approval in the US market, Bharat Biotech said in a press release."COVAXIN has garnered interest from several countries worldwide for supplies and introduction and we are excited to collaborate with Ocugen to bring it to the US market," said Dr. Krishna Ella, Chairman & Managing Director, Bharat Biotech. "In the face of the pandemic, it is incumbent upon all of us to find solutions that have the potential to save lives and restore normalcy to our day-to-day activities. We are very pleased with the safety and immunogenicity demonstrated by the Phase 1 and Phase 2 trials of COVAXIN™ and are encouraged with the progress of the Phase 3 trials in India.